233669-20-0Relevant articles and documents
2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
-
, (2008/06/13)
The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5and R6are independently selected from hydrogen, alkyl and aryl, or pharmaceutically accept
Adamantanecarboximidamide derivatives and their use as NMDA antagonists
-
, (2008/06/13)
The compound of the above formula wherein R1-R5 are independently selected from hydrogen, alkyl and aryl and prodrugs thereof; and pharmaceutically acceptable salts thereof; and use of the compounds in therapy, particularly for treatment of a condition ge
